Interestingly, some of the patients who completed the DCF course experienced rapid progression, while others remained progression-free after more than 2 years of follow-up. The proposed strategy was highly effective with a 1-year progression-free survival (PFS) rate of 47%, setting a new standard in this situation ( 5).
In this trial, DCF was administered for 5 months and was then discontinued, with no further chemotherapy until disease progression. In this context of metastatic or locally advanced recurrent SCCA, the Epitopes-HPV02 multicenter phase II trial assessed the efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen as first-line palliative chemotherapy ( 5). In addition to 15% of patients with SCCA who are diagnosed with de novo metastatic disease, approximately 20% of patients with localized SCCA treated with concurrent chemoradiotherapy subsequently relapse, which may not be amenable to curative therapy ( 4). 2), especially HPV16, which is also implicated in oropharynx carcinoma and other anogenital cancers ( 3). Ninety percent of SCCA are associated with oncogenic human papillomavirus (HPV ref. Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy, but the incidence of SCCA is increasing in both men and women ( 1).
0 kommentar(er)
